John Breitner

John Breitner was recruited to the Douglas to lead a new Centre for Studies on Prevention of Alzheimer’s Disease (StoP-AD). The Centre seeks measurement and detection of change in biomarkers thought to reveal the progress of presymptomatic Alzheimer’s disease. With such ability to measure change, the Centre undertakes clinical trials for Pre-symptomatic Evaluation of Novel or Experimental Treatments for AD (PREVENT-AD).

John Breitner has authored over 200 publications and has mentored more than 15 doctoral and post-doctoral students, almost all of whom have gone on to hold full-time academic appointments.


Research team

John Breitner, MD

Associate Directors
Pierre Étienne, MD
Judes Poirier, PhD


Pierre Bellec, Ph.D.
Veronique Bohbot, Ph.D.
Mallar Chakravarty, Ph.D.
Louis Collins, Ph.D.
Claudio Cuello, Ph.D.
Pierre Etienne, M.D.
Alan C. Evans, Ph.D.
David Fontaine, Ph.D.
Serge Gauthier, M.D.
Rick Hoge, Ph.D.
Gerhard Multhaup, Ph.D.
Vasavan Nair, M.D.
Judes Poirier, Ph.D.
Jens Pruessner, Ph.D.
Natasha Rajah, Ph.D.
Pedro Rosa-Neto, M.D., Ph.D.
Sylvia Villeneuve, Ph.D.


Marianne Dufour
Jennifer Tremblay-Mercier
Cécile Madjar